UBS analyst Joshua Spector upgrades Westlake (NYSE:WLK) from Sell to Neutral and raises the price target from $92 to $95.
New Data Show Roche’s Self-Administered Blood Disorder Candidate Achieves Disease Control
Roche Group Holdings AG's (OTC: RHHBY) data from the global phase 3 COMMODORE 1 and 2 studies e